Inquiry Basket
Loading ......
Aravan virus (ARAV) is a zoonotic RNA virus belonging to the genus Lyssavirus within the family Rhabdoviridae. It was first isolated in 1991 from a lesser mouse-eared bat (Myotis blythii) in Kyrgyzstan and represents one of several recently identified Eurasian bat lyssaviruses. As a member of the lyssavirus genus, ARAV is related to the classic rabies virus (RABV) and poses a potential public health threat, as it is capable of causing a fatal encephalomyelitis indistinguishable from rabies in humans and other mammals. While documented human cases are absent, its detection in bats across Central Asia, serological evidence of human exposure, and demonstrated pathogenicity in animal models classify it as an emerging pathogen of concern.
The discovery of Aravan virus expanded the known diversity and geographic range of Old World bat lyssaviruses. Unlike the canine-mediated rabies cycle familiar in many regions, viruses like ARAV are maintained in independent enzootic cycles within specific bat species. This presents distinct surveillance and control challenges, as human exposure is typically sporadic and occurs through bat bites or scratches. While RABV vaccines provide some cross-protection, their efficacy against divergent lyssaviruses like ARAV can be incomplete, raising concerns about the adequacy of current medical countermeasures. Research into ARAV and its relatives is crucial for understanding lyssavirus evolution, assessing the true burden of bat-associated rabies encephalitis, and preparing for potential spillover events in regions where these viruses circulate.
| Host Targets | Details |
| Microtubule-Associated Proteins (MAPs) | Required for retrograde axonal transport of ARAV from peripheral cells to the CNS. Inhibiting MAPs (e.g., dynein) could block viral dissemination to the CNS, preventing the development of encephalitis. Microtubule inhibitors such as paclitaxel have been shown to block RABV transport, and similar compounds could be tested for ARAV. |
| Interferon Regulatory Factors (IRFs) and STAT Proteins: | Key regulators of the IFN response, which are targeted by the ARAV P protein for immune evasion. Activating IRF3, IRF7, or STAT1 could restore the host IFN response and inhibit ARAV replication. Small-molecule activators of these proteins, or inhibitors of P protein-IRF/STAT interactions, could enhance host immunity against ARAV. |
| Endosomal Sorting Complex Required for Transport (ESCRT) Machinery | Involved in viral budding and release, as observed in other rhabdoviruses. The ESCRT complex mediates membrane scission during viral budding, and inhibiting ESCRT components (e.g., Tsg101, Vps4) could block ARAV release from infected cells. Small-molecule inhibitors of ESCRT proteins have been developed for other viruses and may be repurposed for ARAV. |
| Host Cell Receptors (Putative) | While the exact ARAV receptor is unknown, candidate receptors include nicotinic acetylcholine receptors (nAChRs), neural cell adhesion molecules (NCAMs), and low-density lipoprotein receptor-related protein 1 (LRP1), which are used by other lyssaviruses. Targeting these receptors with blocking antibodies or small molecules could prevent ARAV entry into host cells. For example, antibodies against nAChR α7 subunits have been shown to block RABV entry, and similar strategies could be applied to ARAV. |
Pre-exposure Prophylaxis (PrEP): Standard RABV cell-culture vaccines are recommended for individuals at high risk of exposure (e.g., bat researchers, veterinarians in endemic areas). The degree of cross-protection against ARAV requires further study but is likely partial.
Post-exposure Prophylaxis (PEP): Any potential exposure (bat bite/scratch) in an endemic region should be treated as a medical emergency. PEP includes:
Surveillance: Enhanced passive and active surveillance of bat populations and human/animal encephalitis cases in Central Asia is needed.
Public Education: Educating communities about bat-associated rabies risks and the critical importance of seeking PEP after any bat contact.
Inferred from RABV and related lyssaviruses, ARAV pathogenesis is expected to follow a similar course:
Local Replication: Initial low-level replication in myocytes or sensory neurons at the site of inoculation.
Aravan virus is a salient example of the hidden diversity of lyssaviruses circulating in bat reservoirs worldwide. While its documented public health impact is currently minimal, its existence underscores critical vulnerabilities: the incomplete cross-protection offered by existing rabies biologics and the diagnostic blind spot in regions where atypical lyssaviruses circulate. The molecular pathogenesis of ARAV, mirroring that of RABV, offers a suite of potential targets—from the G protein attachment machinery and the P protein interferon antagonist to the host dynein transport system—for next-generation therapeutics and universal lyssavirus vaccines. Proactive research, surveillance, and preparedness focused on viruses like ARAV are essential components of a comprehensive strategy to achieve the global goal of zero human deaths from rabies and all rabies-related viruses.
| Target | Cat. No. | Product Name | Host | |
| Aravan Virus | DAGA-4108 | Recombinant Aravan virus M, Mammalian cell | Mammalian cells | Inquiry |
| DAGA-4109 | Recombinant Aravan virus M, Baculovirus | Baculovirus | Inquiry | |
| DAGA-4110 | Recombinant Aravan virus M, E.coli | E. coli | Inquiry |
Loading ......
